Medable's $2.1 Billion Valuation Marks Major Milestone as Healthcare Tech Platform Raises $304 Million

Digital clinical trial innovator Medable has closed a substantial Series D funding round valued at $304 million, pushing the company’s valuation to $2.1 billion. The investment signals strong market confidence in decentralized trial technology and positions Medable as the industry frontrunner in transforming how pharmaceutical development operates globally.

Blackstone Growth, GSR Ventures, and Tiger Global co-led this financing round, with additional support from existing backers Sapphire Ventures and WTI. This marks Medable’s fourth major capital injection within 18 months, bringing total funding to $521 million—a testament to accelerating investor interest in the patient-centric research sector.

Redefining Clinical Trial Efficiency

Medable’s cloud-based platform has fundamentally altered how clinical trials function across geographies. The company currently operates 150+ decentralized and hybrid trials spanning 60 countries, engaging over one million patients and research participants. These deployments have yielded remarkable operational metrics: enrollment speeds have tripled, patient retention rates reach 90 percent, and trial costs have dropped by half compared to traditional methodologies.

Dr. Michelle Longmire, CEO and co-founder, emphasized the strategic importance of this funding: “The life sciences industry must sustain innovation velocity. Decentralized technologies have proven essential during recent global health challenges, and we’re committed to dismantling barriers that slow drug development. Our goal is enabling therapies to reach patients worldwide at unprecedented speed.”

Investment Thesis and Market Expansion

Ram Jagannath, Global Head of Healthcare for Blackstone Growth, highlighted the transformative potential: “Medable sits at the center of a fundamental restructuring in clinical research methodology. We’re investing in a business that’s expanding access to trials for patient populations across every continent.”

Dr. Sunny Kumar from GSR Ventures added: “Medable’s devotion to patient experience, technological innovation, and rigorous quality standards has solidified its leadership position. Supporting Michelle’s vision of accelerating therapy delivery remains compelling.”

Jeff Kindler, former Pfizer chief and Centrexion CEO, characterizes the opportunity as transformative: “Cumbersome and costly trial processes remain a critical constraint in pharmaceutical innovation. Strategic technology investments can unlock significant gains in speed while preserving safety and effectiveness standards.”

Strategic Capital Deployment

The new capital will fuel three core initiatives: expanding global infrastructure and market reach, deepening SaaS platform capabilities and integration with partner ecosystems, and advancing remote patient monitoring and site-enablement technologies. Medable aims to help pharmaceutical, biotech, and research organizations accelerate medicine development while maintaining clinical rigor.

Medable’s positioning in the decentralized clinical trial space reflects broader industry recognition—the company recently earned “Leader” designation in Everest Group’s industry assessment, validating its product excellence and market impact as healthcare increasingly adopts distributed research models.